A comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California

  • Post author:
  • Post category:

We aim to markedly expand access of all Californians to outstanding cell and gene therapy trials for multiple conditions with unmet treatment needs. We will also contribute with excellence to…

Continue ReadingA comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California

A Translating Center designed to expedite the development and delivery of high quality stem cell therapies to patients

  • Post author:
  • Post category:

A successful partnership, resulting in the creation of a Translating Center recognized as the leader in providing end-to-end preclinical development services (preclinical research, CMC, regulatory) to accelerate the availability of…

Continue ReadingA Translating Center designed to expedite the development and delivery of high quality stem cell therapies to patients

An Accelerating Center designed to expedite the development and delivery of high quality stem cell therapies to patients

  • Post author:
  • Post category:

A successful partnership, resulting in the creation of an Accelerating Center recognized as the leader in providing end-to-end clinical development services (regulatory, clinical, data management) to accelerate the availability of…

Continue ReadingAn Accelerating Center designed to expedite the development and delivery of high quality stem cell therapies to patients

A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

  • Post author:
  • Post category:

Therapeutic Candidate or Device iPSC-derived CD19 CAR T cell therapy Indication Systemic Lupus Erythematosus Therapeutic Mechanism Depletion of CD19+ B cells and plasmablasts Unmet Medical Need Potential for drug-free remission…

Continue ReadingA Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

  • Post author:
  • Post category:

Therapeutic Candidate or Device SENTI-202 is an allogeneic off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cellular therapy targeting CD33 and/or FLT3 malignancies. Indication CD33 and/or FLT3 expressing hematologic malignancies,…

Continue ReadingSelective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies